" class="no-js "lang="en-US"> Avacta Group - Medtech Alert
Wednesday, March 22, 2023
Avacta Group | Pharmtech Focus

Avacta Group

About Avacta Group

Avacta Group

Our mission is to shape the future of medicine by developing safe and efficacious drugs, and high performing diagnostics, based on our proprietary Affimer® and pre|CISIONᵀᴹ platforms.

The Affimer® platform is a novel class of biotherapeutic based on a naturally occurring human protein. It is Avacta’s proprietary therapeutic platform with its intellectual property covered by several patent families.

Avacta’s proprietary pre|CISIONᵀᴹ targeted chemotherapy platform, releases active drug only in the tumour, thereby limiting systemic exposure and improving the overall safety and therapeutic potential of these powerful anti-cancer treatments. Avacta expects to take its first pre|CISIONᵀᴹ drug candidate, AVA6000, a targeted form of the standard-of-care Doxorubicin, into the clinic by the second half of 2021.

By combining these two platforms the Company is building a pipeline of novel cancer therapies with the aim of creating effective treatments for all cancer patients including those who do not respond to existing immunotherapies.

Avacta’s diagnostics division, based in Wetherby, UK., utilises it’s proprietary Affimer® platform to develop high performing diagnostics and works with partners world-wide to develop Affimer reagents with the objective of establishing royalty bearing license deals.

Related Story

Avacta Announces AffyXell Expands Its Strategic Partnership With GenScript ProBio

May 17 2022

Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company developing innovative cancer therapies […]

Avacta Establishes New Therapeutics Headquarters at Scale Space, Imperial College White City Campus

May 11 2022

Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company developing innovative cancer therapies […]

AffyXell Partners with Biocytogen and the Korea Non-clinical Technology Support Center

April 11 2022

Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful […]

Avacta Appoints Dr Christina Coughlin as Non-Executive Director

March 21 2022

Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and […]

Avacta Selects Second pre|CISION™ Pro-drug Candidate for Development

January 18 2022

Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and […]

Avacta Provides Update on AffiDX ® SARS-CoV-2 Antigen Lateral Flow Test and Detection of the Omicron Variant

January 10 2022

Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and […]

Avacta Announces AffiDX ® SARS-CoV-2 Antigen Lateral Flow Test Receives CE Mark for Consumer Self-Testing

December 22 2021

Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and […]

Avacta Announces AffiDx SARS-CoV-2 Antigen Lateral Flow Test Detects the Omicron Variant

December 15 2021

Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful […]

Avacta Announces FDA Approval of its Investigational New Drug (IND) Application for AVA6000

November 29 2021

Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and […]

Avacta Group Achievement of Pre-clinical Development Milestone in LG Chem Life Sciences Partnership

September 29 2021

Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and […]